{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:48:26Z","timestamp":1782031706399,"version":"3.54.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012287","name":"Andrew Sabin Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijrobp.2025.03.066","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:50:34Z","timestamp":1776347434000},"page":"295-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Setting the TRAP for Oligoprogressive Prostate Cancer: The Impetus for Prospective Evidence"],"prefix":"10.1016","volume":"125","author":[{"given":"Alexander D.","family":"Sherry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan B.","family":"Ludmir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-1327","authenticated-orcid":false,"given":"Chad","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.03.066_bib0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijrobp.2025.02.046","article-title":"Stereotactic body radiation therapy for oligoprogressive disease in androgen-suppressed prostate cancer: Primary endpoint analysis of the TRAP trial","volume":"125","author":"Patel","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.066_bib0002","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: A randomized phase II trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.066_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.2025.43.5_suppl.22","article-title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer: A randomized phase II trial (GROUQ-PSC 9)","volume":"43","author":"Niazi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.066_bib0004","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.2025.43.5_suppl.140","volume":"43","author":"Sherry","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.066_bib0005","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.euo.2024.04.003","article-title":"Progression-directed therapy in oligoprogressive castration-resistant prostate cancer: Final results from the prospective, single-arm, phase 2 medcare trial","volume":"7","author":"Rans","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.066_bib0006","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: The EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.066_bib0007","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.066_bib0008","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.066_bib0009","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): A randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.066_bib0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162500286X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162500286X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:30:42Z","timestamp":1782030642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162500286X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S036030162500286X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.066","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Setting the TRAP for Oligoprogressive Prostate Cancer: The Impetus for Prospective Evidence","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.02.046","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}